Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades. The FDA says the okay to use Victoza (liraglutide) in paediatric patients aged 10
WASHINGTON—U.S. Senator Mike Braun questioned Novo Nordisk CEO, Lars Fruergaard Jørgensen, at the Senate Health, Education, Labor and Pensions Committee hearing on Tuesday about the high prices of the company’s weight loss drug, Ozempic, in the United States. Partial Transcriptof ...
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company...
Novo Holdings, which operates under Novo Nordisk’s owner the Novo Nordisk Foundation, is laying out $16.5 billion to snap up contract manufacturing giant Catalent, the companiesrevealedMonday. Specifically, Novo Holdings is acquiring all outstanding shares of the CDMO for $63.50 ...
Yangchao ChenMintage Journal of Pharmaceutical and Medical Sciences
Americans are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk’sweight-lossand diabetes drugs but cannot always fill them because ofsupply issuesandinsurance hurdles, according to their doctors. Those frustrations, along with the medicines’high cost, are pushing patients tocheaper ...
Novo Nordisk is the market leader in international operations with a GLP-1 value market share of 69%. Ozempic continues its GLP-1 market leadership with 46.6% market share. We're also pleased to see Rybelsus increasing its market share to more than 16%, driven by solid uptake across geograp...
Novo Nordisk is taking another Florida pharmacy to court after allegedly finding impurities in its compounded drugs marketed as semaglutide, including one sample that was … Sign up to read this ...
Good day, and thank you for standing by. Welcome to the Q2 2023 Novo Nordisk A/S Earnings Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Daniel Bohsen, Head of Inv...
The majority of Novo Nordisk medicines are used for treating chronic diseases. However, during the period of social distance implemented in many markets, fewer new patients are temporarily expected to initiate treatment. This especially impacts launched products and products with a short stay time. Ag...